Vicore Pharma AB
Jacob Gunterberg possesses extensive experience in the pharmaceutical and financial sectors, currently serving as a Board Member at Vicore Pharma AB since September 2018. Gunterberg has held prominent roles including Partner at HealthCap from July 2007 to April 2022 and Director positions at SynOx Therapeutics, Carisma Therapeutics, Trimb Healthcare, MIPS AB, and OxThera during various periods. Additionally, Gunterberg was a Founding Partner at Hjalmarsson & Gunterberg Corporate Finance AB from June 2000 to June 2007 and worked as a Director at Aros Securities from September 1993 to March 2000. Gunterberg's educational background includes studies at Lund University and the University of St. Gallen.
This person is not in the org chart
This person is not in any teams
Vicore Pharma AB
1 followers
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.